항암 펩타이드 치료제 시장 : 시장 기회, 승인된 의약품 용량, 가격, 매출 및 임상시험 분석(-2031년)

Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031 Report Finding & Highlights:

• Research Methodology
• Global Cancer Peptide Drug Market Opportunity: > USD 25 Billion By 2031
• Global & Regional Market trends Insight
• Insight On Cancer Peptides In Clinical Trials: > 240 Drugs
• Cancer Peptide Clinical Trials Insight By Company, Country, Indication & Phase
• Number Of Approved Cancer Peptides: > 30 Drugs
• Insight On Approved Cancer Peptide By Brand Name, Indication, Company, Location, Collaborations
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Venom Peptides As New Opportunity For Cancer Peptide Therapy

Need For Peptide Therapeutics In Cancer Treatment & Why This Report?

Global cancer peptide therapeutics market has transformed itself into a scientifically diverse yet active clinical field in cancer drug development due to its highly desirable potential for molecularly targeted and versatile cancer treatment modalities. Peptides hold a key position as they can be rationally designed to target and modulate complex cancer biology: receptor signaling pathways, intracellular protein interactions, cancer immune system targeting, and delivery to the tumor environment. As such, they represent a significant aspect of the next generation oncology research and development market.

In this report, we undertake a comprehensive analysis of global cancer peptide therapeutics market, highlighting clinical development efforts, partnership and collaboration activities, investment trends, and the development of novel scientific avenues, all aimed at assisting investors, pharmaceutical companies and stakeholders make their decision in the cancer treatment landscape with an effective use of peptide based innovative approaches.

Clinical Development Insight Included In Report

The report offers an extensive analysis of current oncology programs involving peptides at various levels of clinical development, starting with the first human studies to advanced stages and even registration studies, as well as the further assessment of already existing peptide therapies. The scope of clinical trials covers various cancer types, both commonly encountered and quite rare ones, thus demonstrating the increasing importance of peptide based solutions in oncology treatment.

The analysis also covers the important characteristics of these clinical trials, including whether monotherapy or combinations were used, targeted patient populations, lines of therapy, routes of administration, clinical trial designs, sponsoring organizations, development partners, and licensing agreements. The report also provides an assessment of the results achieved in terms of efficacy and safety from clinical trials using peptides in oncology therapies, specifically focusing on the percentage of responders, progression free survival rates, and overall survival figures. It further evaluates the potential for peptides to be used in combination therapies with chemotherapy, immunotherapies, and other antineoplastic treatments.

Major Companies Driving Peptide Therapeutics R&D

In this regard, the peptide oncology landscape includes strong contributions from big pharma companies as well as small biotechnology firms. In particular, significant involvement of companies like Eli Lilly and Novartis in peptide based approaches through licensing, partnerships, and radioligand development programs can be observed. Peptide based techniques are currently used by these companies in the framework of their comprehensive oncology pipelines as part of combination approaches or targeted treatment strategies for a wide variety of cancers.

Additionally, smaller biotechnology companies like Avacta Therapeutics and Gate2Brain have been actively developing promising peptide based anticancer compounds in preclinical and clinical studies. Such companies have been collaborating with more mature players on translating novel peptides into treatment candidates within the field. The involvement of big pharma in this field, together with the innovative efforts of emerging biotechnology firms, ensures ongoing progress in peptide oncology.

Report Indicating Future Development Of Cancer Peptide Therapeutics

This report outlines an organized assessment of the ongoing development of peptide therapies against cancer, detailing developments from early research programs through to clinical trials and even to later stage validation studies. Peptides continue to demonstrate increasing utility in targeting multiple cancers, ranging from more common solid cancers to some of the rarer forms. One particular area of interest is the use of synthetic peptides in targeting protein-protein interactions within the cell and oncogenic signal transduction pathways involved in driving tumor proliferation and survival.

Moreover, developments in tumor penetration and delivery of peptides in cancer are noted, along with efforts towards improving selectivity within the tumor environment without causing toxicity to other parts of the body. In addition, developments in the peptide based immunotherapy approaches, including those targeting T-cell proliferation and stimulation, have been discussed, alongside peptide guidance of radiopharmaceuticals to tumors. Overall, this shows a wide range of ongoing progress in the field of peptide therapy in oncology

Table of Contents

1. Introduction To Peptide Therapeutics

• 1.1 Overview Of Peptide Therapeutics
• 1.2 Classification Of Anticancer Peptides
• 1.3 Designing & Functioning of Peptide Drugs
• 1.4 Significance Of Peptides As Cancer Therapeutics
• 1.5 Role of Peptides in Cancer Immunotherapy

2. Different Approaches Of Peptides In Cancer Therapeutics

• 2.1 Hormonal Peptides
• 2.2 Peptide Based Radionuclide Drug Carriers
• 2.3 Peptide Vaccines
• 2.4 Cytotoxic Drug Carriers
• 2.5 Anticancer Peptides
• 2.6 Tumor-Targeting and Cell-Penetrating Peptides
• 2.7 Peptide Nanomedicines
• 2.8 Receptor Antagonist and PPI-Modulating Peptides
• 2.9 Emerging Approaches

3. Global Cancer Peptide Drug Market Insight

• 3.1 Current Market Scenario
• 3.2 Future Market Opportunities

4. Cancer Peptide Research & Market Trends by Country

• 4.1 US
• 4.2 China
• 4.3 Europe
• 4.4 Canada
• 4.5 UK
• 4.6 Australia
• 4.7 Japan
• 4.8 South Korea
• 4.9 India
• 4.10 Middle East
• 4.11 Latin America

5. Cancer Peptide Research & Market Trends By Indication

• 5.1 Breast Cancer
• 5.2 Hematological Malignancies
• 5.3 Urothelial Cancer
• 5.4 Prostate Cancer
• 5.5 Lung Cancer
• 5.6 Skin Cancer
• 5.7 Gastrointestinal Cancer
• 5.8 Gynecological Cancer
• 5.9 CNS Cancers

6. Marketed Cancer Peptides Drugs & Generics Insight - Availability, Cost, Dosage, Indication & Patent Insight

• 6.1 Firmagon (Degarelix)
• 6.1 Eligard (Leuprolide)
• 6.2 Lupron (Leuprolide Acetate)
• 6.3 Gonax (Degarelix Acetate)
• 6.4 Trelstar (Triptorelin)
• 6.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
• 6.6 Velcade (Bortizomib)
• 6.7 Ninlaro (Ixazomib)
• 6.8 Kyprolis (Carfilzomib)
• 6.9 Istodax (Romidepsin)
• 6.10 Zoladex (Goserelin)
• 6.11 Cosmegen (Dactinomycin)
• 6.12 Somatuline Depot (Lanreotide)
• 6.13 Sandostatin/ Sandostatin LAR (Octreotide Acetate)
• 6.14 Bynfezia Pen (Octreotide)
• 6.15 Lutathera (Lutetium Lu 177 dotatate)
• 6.16 Mepact (Mifamurtide)
• 6.17 Netspot (Gallium Ga 68 dotatate)
• 6.18 Camcevi (Leuprolide)

7. Marketed Cancer Peptides Drugs Sales Insight

• 7.1 Kyprolis
• 7.2 Zoladex
• 7.3 Lutathera
• 7.4 Sandostatin
• 7.5 Somatuline
• 7.6 Decapeptyl SR
• 7.7 Ninlaro
• 7.8 Velcade
• 7.9 Lupron

8. Global Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication & Phase

• 8.1 Research
• 8.2 Preclinical
• 8.3 Phase 0
• 8.4 Phase I
• 8.5 Phase I/II
• 8.6 Phase II
• 8.7 Phase II/III
• 8.8 Phase III
• 8.9 Preregistration
• 8.10 Registered

9. Marketed Peptide Cancer Drugs Clinical Insight By Company, Country & Indication

10. Venom Peptides: New Era For Cancer Peptide Therapy

• 10.1 Bee Venom-Derived Peptides
• 10.2 Scorpion Venom-Derived Peptides
• 10.3 Snake Venom-Derived Peptides
• 10.4 Spider Venom-Derived Peptides
• 10.5 Cone Snail Venom-Derived Peptides

11. Global Peptide Cancer Drug Market Dynamics

• 11.1 Favorable Market Parameters & Opportunities
• 11.2 Commercialization Challenges & Strategic Solutions

12. Therapeutic Peptide Targets

• 12.1 Signal Transduction Pathways
• 12.2 Cell Cycle Regulators
• 12.3 Apoptosis/Cell-Death Modulators
• 12.4 Tumor Suppressor Targeting peptides
• 12.5 Transcription Factor-Targeting Peptides
• 12.6 DNA Repair Pathway Inhibitors
• 12.7 Anti-Angiogenic Peptides
• 12.8 Immunomodulatory Peptides
• 12.9 Membrane-Disrupting/Oncolytic Peptides

13. Peptide Drugs v/s Conventional Cancer Therapeutics

• 13.1 Peptide Therapeutics v/s Chemotherapy
• 13.2 Peptide Therapeutics vs Immunotherapies
• 13.3 Peptide Therapeutics vs Gene Therapy

14. Competitive Landscape

• 14.1 3B Pharmaceuticals
• 14.2 APIM Therapeutics
• 14.3 AsclepiX Therapeutics
• 14.4 Bicycle Therapeutics
• 14.5 Biohaven Labs
• 14.6 BrightPath Biotherapeutics
• 14.7 Bristol-Myers Squibb
• 14.8 Gnubiotics Sciences
• 14.9 IDP Pharma
• 14.10 Janux Therapeutics
• 14.11 Medikine
• 14.12 Modulation Therapeutics
• 14.13 Novartis
• 14.14 Oncopeptides
• 14.15 Parabilis Medicines
• 14.16 PeptiDream
• 14.17 Perspective Therapeutics
• 14.18 Pharm-Sintez
• 14.19 Sapience Therapeutics
• 14.20 Vigeo Therapeutics